10-K: Allogene Therapeutics 2025 Annual Report: Clinical Progress & Financials

Allogene Therapeutics reports a $190.9 million net loss in 2025, advancing its allogeneic CAR T pipeline with key clinical milestones expected in 2026 and 2027, while managing operational risks and capital needs.

Summary

• Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases.
• The company focuses on three core programs: ALPHA3 (Large B-Cell Lymphoma LBCL), RESOLUTION (Autoimmune Disease AID), and TRAVERSE (Renal Cell Carcinoma RCC).
• The ALPHA3 trial for cema-cel (CD19-targeting) in first-line (1L) LBCL consolidation is ongoing, with interim futility analysis data expected in April 2026 and enrollment completion anticipated by the end of 2027.
• The FCA arm (fludarabine, cyclophosphamide, and ALLO-647) of the ALPHA3 trial was discontinued in August 2025 due to a Grade 5 serious adverse event (fatal disseminated adenovirus infection) attributed to ALLO-647; the trial now proceeds with the FC arm and observation.
• Enrollment in the Phase 1 TRAVERSE trial for ALLO-316 (CD70-targeting) in advanced RCC has been completed; updated data presented in June 2025 showed a 31% confirmed overall response rate (ORR) in patients with high CD70 expression (TPS ≥50%).
• ALLO-316 received Regenerative Medicine Advanced Therapy (RMAT) designation in October 2024 for adult patients with advanced or metastatic RCC.
• The Phase 1 RESOLUTION trial for ALLO-329 (CD19/CD70-targeting) in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc) was initiated in Q2 2025, with initial proof-of-concept data expected in June 2026.
• ALLO-329 received three Fast Track Designations (FTD) from the FDA for SLE, IIM, and SSc in April 2025.
• The net loss for the year ended December 31, 2025, was $190.9 million, a decrease from $257.6 million in 2024.
• As of December 31, 2025, the company had $258.3 million in cash, cash equivalents, and investments, with an expected cash runway into the first quarter of 2028.
• A workforce reduction of approximately 28% was implemented in May 2025, resulting in approximately $3.3 million in cash-based severance and related costs.
• Foresight Diagnostics, the partner for the CLARITY MRD assay used in ALPHA3, was acquired by Natera, Inc. in December 2025 but continues to operate as a standalone subsidiary.
• An arbitration between Cellectis and Servier resulted in the termination of sublicense rights for ALLO-501 but affirmed continued rights for cema-cel; a $20.0 million escrow balance was remitted to the company on February 13, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period marked by continued significant financial losses and a major clinical safety setback (Grade 5 SAE leading to discontinuation of an ALPHA3 arm). While there are positive clinical advancements and regulatory designations, the substantial capital needs and inherent risks of novel therapies in a competitive landscape weigh heavily on the outlook.

Positives

• Advancement of three core clinical programs (ALPHA3, RESOLUTION, TRAVERSE) with multiple anticipated clinical readouts in 2026 and 2027, potentially validating the allogeneic CAR T platform.
• ALLO-316 received Regenerative Medicine Advanced Therapy (RMAT) designation for advanced/metastatic RCC, which may facilitate an efficient development program and expedited review.
• ALLO-329 received three Fast Track Designations (FTD) for SLE, IIM, and SSc, potentially accelerating its development and regulatory review.
• Updated TRAVERSE trial data for ALLO-316 demonstrated a 31% confirmed ORR in CD70 TPS ≥50% RCC patients, with four out of five confirmed responders maintaining ongoing responses, including one in sustained remission for over 12 months, indicating potential for long-term disease control.
• Alignment with the FDA has been reached on the design of a registration trial for ALLO-316 in adult patients with advanced or metastatic RCC.
• The Cellectis-Servier arbitration outcome was favorable for cema-cel, affirming continued sublicense rights and resulting in the remittance of $20.0 million from escrow to the company.
• Net loss decreased to $190.9 million in 2025 from $257.6 million in 2024, and net cash used in operating activities decreased from $200.3 million in 2024 to $149.2 million in 2025.
• The company's cash runway is expected to fund operations into the first quarter of 2028.

Negatives

• The company incurred a net loss of $190.9 million in 2025 and has an accumulated deficit of $2.0 billion, indicating continued unprofitability and substantial capital needs.
• A Grade 5 (fatal) serious adverse event in the ALPHA3 trial's FCA arm led to the discontinuation of that arm and termination of ALLO-647 development, highlighting significant safety concerns with a component of their prior lymphodepletion strategy.
• There is uncertainty regarding whether the FC-only lymphodepletion regimen in ALPHA3 will achieve sufficient lymphodepletion to support optimal cema-cel efficacy.
• A workforce reduction of approximately 28% was implemented in May 2025, incurring $3.3 million in severance costs, reflecting operational scale-down and resource reprioritization.
• The stock price has been volatile and has significantly declined since the option exchange program, resulting in a substantial number of employee options being underwater.
• Reduced manufacturing operations may limit the company's ability to timely support development programs and future commercialization efforts.
• Reliance on Foresight Diagnostics (now Natera) for the CLARITY MRD test introduces risks related to its regulatory approval outside the U.S., logistical challenges, and potential changes in strategic priorities post-acquisition.
• No CAR T therapy has been approved as a first-line consolidation strategy for LBCL, presenting significant regulatory, commercial, and operational risks in this unproven setting.
• Increased interest among investors and large pharmaceutical companies in in vivo cell-engineering technologies may adversely affect the company's ability to raise capital or secure development partnerships for allogeneic therapies.

Risks

• The company has incurred net losses in every period since its inception and anticipates incurring substantial net losses in the future, requiring substantial additional financing.
• Product candidates are based on novel technologies, making it difficult to predict the time and cost of development and the likelihood of obtaining regulatory approval.
• The business is highly dependent on the success of its lead product candidates; failure of any could significantly harm the business.
• Product candidates may cause undesirable side effects (e.g., CRS, ICANS, IEC-HS, prolonged cytopenia, GvHD, T-cell malignancies) that could halt clinical development, prevent regulatory approval, limit commercial potential, or result in significant negative consequences.
• Clinical trials may fail to demonstrate the safety and efficacy of any product candidates, which would prevent or delay regulatory approval and commercialization.
• Risks related to serious adverse events (SAEs) in the discontinued FCA arm of the ALPHA3 trial, including the Grade 5 SAE, could lead to regulatory actions, negative perceptions, and potential product liability claims.
• No CAR T therapy has been approved as part of a first-line consolidation strategy for the treatment of LBCL patients, which presents significant regulatory, commercial, and operational risks.
• The company may encounter substantial delays in its clinical trials or may not be able to conduct trials on expected timelines due to various factors, including patient enrollment difficulties, regulatory consensus, and manufacturing issues.
• Failure to successfully manufacture product candidates, operate its own manufacturing facility (CF1), or obtain regulatory approval for commercial utilization could adversely affect clinical trials and commercial viability.
• Reduced manufacturing operations may limit the company's ability to timely support its development programs.
• Significant competition from other biotechnology and pharmaceutical companies, including autologous, in vivo, and other therapeutic modalities, could adversely affect operating results.
• High dependency on key personnel; failure to attract and retain highly qualified personnel could impede business strategy implementation.
• Disruptions to the operations of the FDA, SEC, and other government agencies (e.g., funding shortages, policy initiatives, staffing reductions) could impair their ability to perform regulatory functions and negatively impact the business.
• Uncertainty exists regarding whether the use of FC without ALLO-647 will achieve sufficient lymphodepletion to support the efficacy of the allogeneic CAR T product candidate in the ALPHA3 trial.
• Heavy reliance on partners, Cellectis and Servier, for access to TALEN gene editing technology for oncology product candidates, with risks of license termination or intellectual property disputes (e.g., Factor Litigation).
• Heavy reliance on Foresight Diagnostics (now Natera) for access to their CLARITY MRD test for identifying eligible patients for the ALPHA3 trial, with risks related to regulatory approval, logistical challenges, and post-acquisition changes.
• The FDA and other comparable foreign regulatory approval processes are lengthy, time-consuming, and subject to change, potentially causing significant delays.
• The FDA or comparable foreign regulatory authorities may disagree with the company's regulatory plan, potentially leading to failure to obtain regulatory approval.
• If approval of a companion diagnostic device (e.g., CLARITY assay) is required and delayed or not obtained, commercialization of the related product candidate will be materially impaired.
• Dependence on intellectual property licensed from third parties; termination of any of these licenses could result in the loss of significant rights.
• Inadequate efforts to protect the proprietary nature of intellectual property could prevent effective competition.
• Third-party claims of intellectual property infringement (e.g., Factor Litigation) may prevent or delay product discovery, development, and commercialization.
• The price of the company's stock has been and may continue to be volatile, leading to potential loss of investment.
• Failure to establish and maintain effective internal control over financial reporting could result in material misstatements and loss of investor confidence.
• Unstable market, economic, and geopolitical conditions may have serious adverse consequences on the business, financial condition, and stock price.
• Sales of a substantial number of shares of common stock by existing stockholders could cause the stock price to fall.
• Adverse or misleading opinions from securities or industry analysts could cause the stock price and trading volume to decline.
• Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception or adversely affect business operations or regulatory approvals.
• Product candidates regulated as biological products may be subject to biosimilar competition sooner than anticipated.
• Even if approved, products may not gain market acceptance among physicians, patients, hospitals, and the medical community.
• Coverage and reimbursement may be limited or unavailable in certain market segments, making profitable sales difficult.
• Healthcare reform initiatives could negatively impact the ability to sell products profitably.
• Environmental, social, and corporate governance (ESG) matters or reporting of such matters could negatively impact the business.

Future Outlook

Allogene Therapeutics expects multiple clinical readouts in Q2 2026, including MRD clearance data from the ALPHA3 interim futility analysis in April 2026 and initial proof-of-concept data from the RESOLUTION trial in June 2026. Enrollment in ALPHA3 is anticipated to be completed by the end of 2027. The company is exploring partnering opportunities for ALLO-316 and other pipeline candidates. Management expects to incur significant expenditures and net losses for the foreseeable future, with current cash, cash equivalents, and investments expected to fund operations into Q1 2028, necessitating additional financing for commercial production and registrational trials.

Management Comments

• "We believe this key difference [allogeneic approach] will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients."
• "These readouts could begin to validate several key scientific and clinical assumptions underlying off-the-shelf CAR T therapy, including biologic activity, safety, and the feasibility of standardized, readily available cell therapy across oncology and autoimmune indications."
• "We believe our technology platform combined with our management teams experience in immuno-oncology and specifically in CAR T cell therapy will help drive the rapid development and, if approved, the commercialization of potentially curative therapies for patients with aggressive cancer or who suffer from autoimmune diseases."
• "We believe establishing our own fully integrated manufacturing operations and infrastructure will allow us to continuously improve the manufacturing process, limit our reliance on contract development and manufacturing organizations (CDMOs) and more rapidly advance the commercialization of any of our product candidates that receive regulatory approval."
• "We believe we currently hold sufficient inventory of cema-cel, ALLO-329, and ALLO-316 to meet our near-term clinical needs based on our current forecasts, including completing our current ALPHA3, RESOLUTION and TRAVERSE trials."
• "We believe that the Foresight Diagnostics assay is highly sensitive and predictive of which patients are likely to relapse."
• "We believe that it will be important that patients receive CAR T therapy as soon as possible following an MRD positive diagnosis, which will not allow for the lengthy manufacturing process of autologous CAR T."
• "We believe this approach [diagnostic and treatment algorithm for IEC-HS] has proven effective by enabling early intervention and effective management, resulting in a safety profile consistent with standard lymphodepletion and active CAR T treatment."
• "We believe we have reached alignment with the FDA on the design of a registration trial for adult patients with advanced or metastatic RCC [for ALLO-316]."

Industry Context

StockSavvy.ai notes that Allogene Therapeutics operates in the highly competitive and rapidly evolving immuno-oncology and autoimmune disease sectors, particularly within CAR T cell therapy. The company's allogeneic, "off-the-shelf" approach aims to overcome the logistical and manufacturing limitations of autologous CAR T therapies, which require individualized patient cell collection and longer wait times. While autologous CAR T therapies like Yescarta, Kymriah, and Breyanzi have gained FDA approval and moved into earlier lines of treatment for various blood cancers, Allogene is pioneering the first-line consolidation setting for LBCL with cema-cel, an unproven but potentially transformative strategy. The emergence of in vivo CAR T and bispecific antibody platforms represents increasing competition, potentially shifting treatment paradigms and intensifying pricing pressures. Allogene's focus on novel targets like CD70 and dual-targeting approaches (CD19/CD70) for solid tumors and autoimmune diseases positions it at the forefront of expanding CAR T applications beyond traditional hematological malignancies, but also introduces unique regulatory and safety challenges.

Comparison to Industry Standards

• Allogene's allogeneic CAR T approach aims to provide readily available treatments faster, more reliably, and at greater scale than autologous CAR T therapies (e.g., Yescarta, Kymriah, Breyanzi), which are burdened by lengthy delivery times (weeks to months) and manufacturing failures (up to 31% of intended patients in registrational trials for Yescarta and Kymriah did not receive treatment).
• The ALPHA/ALPHA2 trials for cema-cel/ALLO-501 in R/R LBCL showed ORR and CR rates (67% and 58% respectively for the selected Phase 2 regimen) comparable to approved autologous CD19 CAR T cell products in similar patient populations.
• The median time to start of treatment for cema-cel in ALPHA/ALPHA2 was two days from study enrollment, significantly faster than autologous CAR T products which often require wait times longer than one month.
• The safety profile of cema-cel in Phase 1, with low rates of CRS and ICANS, permits outpatient use in R/R patients, potentially offering a convenience advantage over some autologous therapies.
• Allogene's RESOLUTION trial for ALLO-329 is evaluating dose levels starting at 20 million CAR T cells, with lymphodepletion regimens including cyclophosphamide alone or no lymphodepletion, contrasting with competitive CAR T programs evaluating doses ranging from 150 million cells (autologous) to nearly 1 billion cells (allogeneic) and often utilizing multi-drug lymphodepletion (e.g., cyclophosphamide + fludarabine).
• The Grade 5 SAE in the ALPHA3 trial's FCA arm (fulminant hepatic failure from disseminated adenovirus infection) attributed to ALLO-647 highlights a specific safety risk associated with Allogene's prior lymphodepletion strategy, which is now being addressed by discontinuing ALLO-647.
• The FDA's January 2024 request for black box warnings on approved autologous CAR T therapies (e.g., Abecma, Carvykti, Kymriah, Yescarta, Breyanzi, Tecartus, Aucatzyl) regarding T-cell malignancies (observed in ~1 in 1,000 patients) indicates a broader safety concern in the CAR T field that Allogene's similar allogeneic therapies may also face.

Corporate Governance

Legal Proceedings

• Factor Bioscience Inc. filed a patent infringement complaint against Cellectis S.A. and its affiliate Cellectis, Inc. on September 26, 2025, alleging infringement of three U.S. patents related to gene-editing techniques (TALEN-based technology). Allogene is not a party to this litigation but relies on Cellectis' TALEN technology for cema-cel and ALLO-316.
• Roche Molecular Systems, Inc. and Roche Sequencing Solutions, Inc. filed lawsuits in July 2024 against Foresight Diagnostics Inc., Stanford University, and Foresight's founders, alleging misappropriation of trade secrets, unfair competition, and breach of contract related to Foresight Diagnostics' PhasED-Seq Circulating Tumor DNA Platform. This litigation was closed on August 29, 2025, with a limited licensing agreement.

Related Party Transactions

• Consulting agreement with Bellco Capital LLC, controlled by Executive Chair Arie Belldegrun, M.D., for advisory services, with payments of $0.8 million in 2025 and $0.7 million in 2024.
• Sublease agreement with Bellco Capital LLC for 2,218 square feet of office space in Los Angeles, California, commenced January 1, 2024, with $0.4 million in rent expense recorded in 2025.
• License Agreement with Overland Therapeutics Inc. (formerly Allogene Overland Biopharm (CY) Limited), a joint venture where Allogene's ownership decreased to 18% after an Organizational Restructuring in May 2024.

Stakeholder Impact

• Shareholders face potential dilution from past and future equity raises and continued stock price volatility due to financial losses, clinical setbacks, and competitive pressures.
• Employees were impacted by a workforce reduction of approximately 28% in May 2025, affecting 61 individuals, and many stock options are underwater, potentially reducing incentive.
• Patients may benefit from novel, off-the-shelf CAR T therapies for aggressive cancers (LBCL, RCC) and autoimmune diseases (SLE, IIM, SSc) if clinical trials are successful, but also face risks of serious adverse events in trials.
• Partners (Cellectis, Servier, Foresight/Natera, MD Anderson) are critical for technology access, clinical development, and commercialization, but face risks from partner performance, intellectual property disputes, or changes in partner strategic priorities.
• Creditors may be impacted by the company's continued net losses and ongoing need for additional financing, which could affect creditworthiness.

Next Steps

• Announce MRD clearance data from the ALPHA3 interim futility analysis in April 2026.
• Anticipate completion of enrollment in the ALPHA3 trial by the end of 2027.
• Plan to announce initial proof-of-concept data from the RESOLUTION trial in June 2026.
• Explore partnering opportunities to advance the ALLO-316 program.
• Seek FDA approval of cema-cel based on the ALPHA3 trial, assuming favorable outcomes.
• Potentially use ALPHA3 data to support EU regulatory approval for cema-cel.
• Activate additional ALPHA3 sites in Australia and South Korea in mid-2026.
• Continue to build a pipeline for allogeneic CAR T cell product candidates in hematological malignancies, solid tumors, and autoimmune diseases.
• Continue to invest in process science, product characterization, and manufacturing to continuously improve manufacturing processes, production, and supply chain capabilities.
• Evaluate the impact of new accounting pronouncements (ASU 2024-03 and ASU 2025-06) on consolidated financial statements and disclosures.
• Manage the divestiture of a donor-material supplier and a viral vector/CDMO business in Q2 2026, including potential qualification of alternative suppliers.

Key Dates

Recommendation

Allogene Therapeutics is a clinical-stage company with a high-risk, high-reward profile. While it has made significant clinical progress, including RMAT and Fast Track designations, and has a clear strategy for its novel allogeneic CAR T platform, the company faces substantial financial losses, requires significant future capital, and has experienced a serious clinical safety event that led to the discontinuation of an ALPHA3 trial arm. The stock has shown extreme volatility and a significant decline. A "hold" recommendation reflects the inherent speculative nature of the investment, acknowledging both the long-term potential of its innovative platform and the immediate financial and clinical challenges. Investors should await further de-risking clinical data, particularly from the upcoming ALPHA3 and RESOLUTION readouts, and clearer paths to commercialization and profitability before considering a more aggressive stance.

Keywords

Allogene Therapeutics, CAR T cell therapy, allogeneic, immuno-oncology, cancer, autoimmune disease, LBCL, RCC, SLE, IIM, SSc, cema-cel, ALLO-316, ALLO-329, ALPHA3 trial, TRAVERSE trial, RESOLUTION trial, gene editing, TALEN, CRISPR, Dagger technology, clinical trials, FDA, RMAT designation, Fast Track designation, minimal residual disease, MRD assay, Foresight Diagnostics, Natera, financial results, net loss, cash runway, biotechnology, pharmaceutical